LPAR1, lysophosphatidic acid receptor 1, 1902

N. diseases: 145; N. variants: 11
Disease: Pulmonary Fibrosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.060 Biomarker disease BEFREE Lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) is in the spotlight because its synthetic antagonist has been under clinical trials for lung fibrosis and psoriasis. 31429777 2019
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.060 Biomarker disease BEFREE In this report, we examined head-to-head the efficacy of a potent inhibitor of ATX (PF-8380), that has not been tested in pulmonary fibrosis models, and an antagonist of LPAR1 (AM095) in bleomycin (BLM)-induced pulmonary fibrosis. 30201409 2018
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.060 Biomarker disease BEFREE Thus, a LPA1 PET radiotracer may be useful for studying lung fibrosis or for developing LPA1-targeting drugs. 28864634 2018
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.060 Biomarker disease BEFREE Knockdown of LPA receptor 1 (LPA1) has been shown to mitigate lung injury and pulmonary fibrosis. 28348461 2017
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.060 Biomarker disease BEFREE Modulation of the pulmonary artery endothelial barrier function by the LPA1 receptor has been shown to drive pulmonary fibrosis in murine models of disease. 23084965 2013
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.060 Biomarker disease BEFREE A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. 20649573 2010